3M DDS Announces New VP & General Manager


3M Drug Delivery Systems recently announced the appointment of James Ingebrand as the new Vice President and General Manager after the retirement of his predecessor, James Vaughan. Mr. Ingebrand has built a 27-year career at 3M, giving him significant insight into the pharmaceutical and healthcare industries.

As Vice President and General Manager, he will assume responsibility for the strategic direction of 3M Drug Delivery Systems’ inhalation, transdermal, topical, and oral drug delivery devices and components, which are manufactured and sold in more than 60 countries and six continents around the world.

“We are pleased to have Jim step into this new role within 3M,” said Brad Sauer, Executive Vice President, 3M Health Care Business. “Jim’s depth of knowledge and understanding of the pharmaceutical industry equip him with outstanding tools to cultivate the innovation that 3M Drug Delivery Systems is known for.”

Mr. Ingebrand’s previous positions within the 3M Drug Delivery Systems Division include roles as a Key Account Manager in the United Kingdom, an Inhalation Program Manager, and a Six Sigma Black Belt. He most recently served as the Global Business Director for the 3M Dental Division and has worked in several other healthcare divisions of 3M, including the 3M Infection Prevention Division and 3M Health Care Specialties Division.

Mr. Ingebrand started his career at 3M in 1984 as a Marketing Analyst in the Corporate Marketing Research Department. He earned his BS in Biochemistry and his MBA from the University of Minnesota.

3M Drug Delivery Systems partners with pharmaceutical and biotech companies to develop pharmaceuticals using 3M’s inhalation or transdermal drug delivery technology. 3M offers a full range of feasibility, development, and manufacturing capabilities combined with regulatory guidance to help bring products to market. In-house resources, including toxicology, regulatory expertise, quality assurance, operations, and marketed product support, are available for each step of the development and commercialization process. This depth of resources is one reason why more than 50% of all metered-dose inhalers worldwide and 80% of all transdermal systems in the US utilize 3M drug delivery technology.